A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes, chronic weight management and obstructive sleep apnea with obesity.
Tirzepatide activates two incretin hormone receptors, GIP and GLP-1, rather than GLP-1 alone. Eli Lilly sells it as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Both are once-weekly injections.
FDA approved Mounjaro in 2022 and Zepbound in 2023, with the sleep apnea indication added in December 2024. FDA declared the tirzepatide shortage resolved in December 2024, ending the shortage-based allowance for compounded copies.
Status reflects public FDA actions and reporting as of October 8, 2026. An advisory committee vote is a recommendation, not an FDA decision, and inclusion on a compounding list is not FDA approval.
Tirzepatide is supported by large randomized programs: SURPASS in type 2 diabetes and SURMOUNT in obesity, where average weight loss exceeded what earlier GLP-1-only drugs achieved in comparable trials. The sleep apnea indication rests on the SURMOUNT-OSA trials.
nnng.com does not publish doses, cycles or protocols for peptides. For approved drugs, the dose comes from the FDA-approved prescribing information and your prescriber. For unapproved compounds there is no established human dose, and numbers that circulate online are usually extrapolated from animal studies or written by sellers. If a clinician has already prescribed a dose, our reconstitution calculator converts that prescribed amount into syringe units. It is arithmetic only and does not suggest a dose.